Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the painful flare-ups associated with the disease. The discovery points to a potential new treatment for the autoimmune disorder and may also allow the use of a simple blood test to detect people at elevated risk for developing the condition.
The promising discovery is among the first to emerge from the School of Medicine’s new affiliation with Inova Health, a collaboration that aims to make medical breakthroughs and advance the battle against disease. In this case, the arthritis discovery originated in the lab of UVA’s Kodi Ravichandran, PhD, and was facilitated by combining his team’s resources and expertise with that of Inova researcher Thomas Conrads, PhD, through a THRIV UVA-Inova seed grant.
Understanding Rheumatoid Arthritis
The new findings about rheumatoid arthritis came in an unexpected fashion. Sanja Arandjelovic, PhD, a research scientist in the Ravichandran group, was seeking to better understand what causes the inflammation associated with inflammatory arthritis when she noted that deleting a gene called ELMO1 alleviated arthritis symptoms in mice. This was particularly surprising because Arandjelovic and Ravichandran initially thought that loss of ELMO1 would result in increased inflammation.
“This was a complete surprise to us initially,” recalled Ravichandran, chairman of UVA’s Department of Microbiology, Immunology and Cancer Biology. “I love those kinds of results, because they tell us that, first, we did not fully comprehend the scientific problem when we began exploring it, and, second, such unexpected results challenge us to think in a different way. Given that rheumatoid arthritis affects millions of people worldwide, we felt the need to understand this observation better.”
Digging deeper into the unusual outcome, the researchers determined that ELMO1 promotes inflammation via their function in white blood cells called neutrophils. Ravichandran described neutrophils as the body’s “first line of defense” because they sense and respond to potential threats. “Normally they are good for us, against many bacterial infections,” he said. “But also there are many times when they produce a lot of friendly fire that is quite damaging to the tissues – when they hang around too long or there are too many neutrophils coming in – in this case, infiltrating into the joints during arthritis.”
The researchers also discovered that there is a natural variation in the ELMO1 gene that can prompt neutrophils to become more mobile and have the potential to invade the joints in greater numbers and induce inflammation. (The potential blood test would detect this variation.)
Here things take a particularly cool turn: Normally, doctors are reluctant to try to block the effect of genes like ELMO1 in people, because such genes can play diverse roles in the body. But Ravichandran believes that ELMO1 is different. “ELMO1 partners with very specific set of proteins only in the neutrophils but not in other cells types we tested,” he said. “So, presumably, you may be able to affect only a select cell type.” This latter result came about from a collaborative study where Conrads’ group at Inova performed sophisticated analysis of ELMO1 proteomic partners in neutrophils, many of which also have previously known links to human arthritis. This provided further validation for the role of ELMO1 in rheumatoid arthritis.
Encouragingly, blocking ELMO1 in lab mice alleviated arthritis inflammation without causing other problems, Ravichandran noted. His laboratory is now seeking to identify drugs that could inhibit the function of ELMO1 and is also designing a test for the variation (also called polymorphism) in the ELMO1 gene.
“This is another example of how fundamental basic research can lead to novel discoveries on clinically relevant problems that affect a large number of people,” Ravichandran said.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Global Rheumatoid Arthritis Drugs Market Review 2016-2018 & Forecast 2019-2025 - ResearchAndMarkets.comon November 13, 2019 at 4:07 pm
The "Rheumatoid Arthritis Drugs Market by Drug Type and by Distribution Channel: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025" report has been added to ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
ATLANTA -- Disease flares were common in rheumatoid arthritis (RA) patients receiving checkpoint inhibitors for comorbid cancers, a researcher said here, but most patients were able to continue to ...
- Evaluating Sarilumab's Efficacy as a Monotherapy in Rheumatoid Arthritison November 13, 2019 at 5:10 am
Monotherapy was a big topic of conversation at the American College of Rheumatology’s annual meeting, held November 8-13 in Atlanta, Georgia, and 2 abstracts highlight the efficacy of sarilumab as a ...
- Can You Breastfeed if You Have Rheumatoid Arthritis?on November 12, 2019 at 10:48 am
Women with rheumatoid arthritis (RA) and other rheumatic conditions who want to breastfeed their newborns are generally able to so. That’s the finding from research presented at the 2019 annual ...
- Rheumatoid arthritis: biologics useful in young and old alikeon November 11, 2019 at 2:29 pm
A new study presented at the 2019 ACR/ARP Annual Meeting says that all rheumatoid arthritis (RA) patients, irrespective of their age, benefit to a similar extent from the use of biologic drugs in ...
- Study compares ultrasound versus conventional strategies in early rheumatoid arthritison November 11, 2019 at 1:22 pm
Researchers have found that using the information form ultrasound technology in the treatment protocol did not affect the outcome of the patients with Rheumatoid Arthritis (RA). The study titled, ...
- New Studies Demonstrate the Predictive Value of the Vectra Test in People Diagnosed with Rheumatoid Arthritis Nasdaq:MYGNon November 9, 2019 at 6:57 pm
The key findings are that the Vectra test predicts the risk of radiographic progression (RP) within one year, and the Vectra score, in combination with other clinical measures, predicts the risk of a ...
- New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profileon November 9, 2019 at 4:01 pm
The FINCH studies in rheumatoid arthritis are among several clinical trials of filgotinib in inflammatory diseases, which also include the EQUATOR Phase 2 program in psoriatic arthritis, the TORTUGA ...
- Rheumatoid Arthritis Treatment Market 2019 Healthcare, Clinical Reviews, Analysis – Roche, Johnson & Johnson, AbbVie, Eli Lilly,on November 8, 2019 at 6:06 am
Nov 08, 2019 (Market Insight Reports via COMTEX) -- The report presents an in-depth assessment of the Rheumatoid Arthritis Treatment including enabling technologies, key trends, market drivers, ...
- Rheumatoid Arthritis Drugs Market: Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts Report 2019-2024on November 7, 2019 at 9:15 pm
Nov 08, 2019 (The Expresswire) -- Rheumatoid Arthritis Drugs Market Report studies the global Rheumatoid Arthritis Drugs market status, competition landscape, market share, growth rate, future trends, ...
via Bing News